Analysis of CCLE NMT1 or NMT2 expression data (Supplementary Fig. 15) reveals that in addition to be overexpressed in some cancers (aka the current dogma), NMT expression levels are actually lower in other cancers, many of which are of hematological origin. This evidence concerns the gene NMT2 and cancer.